Oruka Therapeutics (ORKA) Cash from Investing Activities (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Cash from Investing Activities of -$14.4 million for Q1 2026, down 133.68% year-over-year from $42.9 million in Q1 2025, and up 34.44% quarter-over-quarter from -$22.0 million in Q4 2025.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$14.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 133.68% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$154.0 million (up 46.37% YoY), while the FY2025 annual figure was -$96.7 million, up 70.69% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$14.4 million, up from -$22.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $42.9 million in Q1 2025, with the low at -$330.0 million in Q4 2024.
- The 4-year median for Cash from Investing Activities is -$7.3 million (2024), against an average of -$55.2 million.
- Peak annual rise in Cash from Investing Activities reached 93.33% in 2025, while the deepest fall reached 71507.6% in 2025.
- Oruka Therapeutics' Cash from Investing Activities stood at -$2000.0 in 2022, then plunged by 16497700.0% to -$330.0 million in 2024, then surged by 93.33% to -$22.0 million in 2025, then surged by 34.44% to -$14.4 million in 2026.
- Business Quant data shows ORKA's Cash from Investing Activities at -$14.4 million in Q1 2026, -$22.0 million in Q4 2025, and -$122.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - | -410.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -410.95 Mn |
| Mar 31, 2026 | -14.44 Mn |
| Dec 31, 2025 | -22.02 Mn |
| Sep 30, 2025 | -122.45 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 42.87 Mn |
| Dec 31, 2024 | -329.96 Mn |
| Sep 30, 2024 | -171,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -14,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | -6,000.00 |
| Dec 31, 2020 | -13,000.00 |
| Jun 30, 2020 | -3,000.00 |
| Mar 31, 2020 | -3,000.00 |
| Dec 31, 2019 | -2,000.00 |
| Sep 30, 2018 | -3,000.00 |
| Mar 31, 2018 | 3.05 Mn |
| Dec 31, 2017 | 4.75 Mn |